Drugs / KD6001
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05230290 | Sep 2020 → Jul 2022 | neoplasm | Shanghai Kanda Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05906524 | Apr 2024 → Apr 2025 | hepatocellular carcinoma | Shanghai Kanda Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05723432 | Mar 2023 → Dec 2024 | melanoma | Shanghai Kanda Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KD6001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05723432 ↗ |
| Route | Intravenous | “Solution for intravenous injection” NCT05230290 ↗ |